Insilico Medicine, a U.S.-based, Hong Kong–listed AI drug discovery company, is launching a new service that will train general-purpose large language models, like OpenAI’s GPT or Alibaba’s Qwen, to handle biology and chemistry tasks.
Generalist models “fail miserably” at the benchmarks used to measure how AI performs scientific tasks, Alex Zhavoronkov, Insilico’s founder and CEO, told Fortune. “You test it five times at the same task, and you can see that it’s so far from state of the art … It’s basically worse than random. It’s complete garbage.”
